Option chain shows key data for Tevogen Bio Holdings's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Tevogen Bio Holdings.

Tevogen Bio Holdings (NASDAQ:TVGN) Stock, Option Chain

Tevogen Bio Holdings

Tevogen Bio Holdings Inc a clinical-stage specialty immunotherapy company harnessing CD8+ cytotoxic T lymphocytes ("CD8+ CTLs" or "CTLs"), to develop off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders.

benzingaai2023_stock_market_trading_setup_close_up_of_multipl_9ea2f44f-9171-417b-a64e-58bbbd995de1_0

News

Contracts

Movers

MSFT

TVGN

Tevogen Bio Holdings Inc (NASDAQ:TVGN) shares are trading higher Monday after the company announced an expanded AI collaboration with Microsoft Corp (NASDAQ:MSFT).

What&#39;s Going On With Tevogen Bio Stock Today?

Closeup,Of,Wall,St.,Street,Sign,And,Large,New,York

Equities

Futures

Economics

Federal Reserve

Pre-Market Outlook

Markets

Trading Ideas

AAPL

AMZN

GOOG

GOOGL

LGTY

NVDA

SANM

TSLA

TWLO

U.S. stock futures dropped sharply on Monday after China released DeepSeek, an AI model that demonstrates high performance at a lower cost.

US Stock Futures Tumble As DeepSeek Buzz Jolts Big Tech: Expert Says The Chinese AI Model Is Yet To Prove Its Viability At Lower Cost In Long Term

Recent Gains

ACON

ALUR

ASST

AVBP

CNOB

DWTX

HSTM

IPHA

MDXG

The Marygold Companies, Inc. Common Stock

MGLD

MULN

ONCO

PXLW

RMBI

VINC

Why Logility Supply Chain Solutions Shares Are Trading Higher By Over 23%; Here Are 20 Stocks Moving Premarket

Tevogen Bio Holdings Inc

UBS analyst Gregg Orrill maintains PG&amp;E (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PCG#NYSE">PCG</a>) with a Buy and lowers the price target from $24 to $22.

Price Target

Analyst Ratings

UBS Maintains Buy on PG&E, Lowers Price Target to $22

UBS analyst Ashwani Verma maintains Teva Pharmaceutical Indus (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>) with a Buy and lowers the price target from $30 to $27.

TEVA

UBS Maintains Buy on Teva Pharmaceutical Indus, Lowers Price Target to $27

UBS analyst Timothy Arcuri maintains Western Digital (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WDC#NASDAQ">WDC</a>) with a Neutral and lowers the price target from $78 to $70.

UBS Maintains Neutral on Western Digital, Lowers Price Target to $70

Tesla Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) CEO Elon Musk has turned increasingly political in recent years, a move that may have hurt the brand value of the <a href="https://www.benzinga.com/news/global/25/01/43172806/tesla-lost-15-billion-in-brand-value-in-2024-report-says-did-elon-musks-political-push-hurt-ev-giant">electric vehicle company.</a>
While Musk is OK with supporting President Donald Trump and the end of the $7,500 federal tax credit, the billionaire also has his eyes set on a sustainable future.
What Happened: A proposed end to the <a href="https://www.benzinga.com/trading-ideas/25/01/43116755/trumps-plan-to-end-7500-ev-tax-credits-could-be-devastating-for-telsa-rivals-poll-says-could-be-bullish-for-elon-musks-company">$7,500 EV tax credit </a>by Trump is one of the biggest storylines for the electric vehicle sector and Musk is a supporter of making such a change.
Musk and Tesla analysts believe the decision to end the credit would be bad for Tesla in the short term, but ultimately benefit the company in the long term as it would be tougher on competitors.
The Tesla CEO was asked about electric vehicle policies under Trump during the company's<a href="https://www.benzinga.com/news/earnings/25/01/43321103/tesla-q4-earnings-highlights-revenue-miss-eps-miss-ev-updates-automaker-says-2025-will-be-a-seminal-year"> fourth-quarter earnings call.</a>
An analyst asked about plans to reverse the "EV mandate" and potential slowdowns of electric vehicle demand in the U.S. due to regulations.
Musk shied away from the question but did highlight his continued belief on electric vehicles being a big part of the future.
"At this point, I think that sustainable transport is inevitable," Musk said, as shared by <a href="https://insideevs.com/news/749018/musk-q4-call-ev-regulations/">InsideEVs</a>. "I'm highly confident that all transport will be autonomous, electric, including aircraft, and that simply, it can't be stopped."
Musk went on to compare the rise of electric vehicles to the introduction of the internal combustion engine.
"Even if you've been the biggest horse advocate on Earth … like, ‘horses are the way, not these new-fangled automobiles,' you can't stop the advent of the automobile and you can't stop the advent of electric cars. It's going to happen."
The Tesla CEO said the only thing holding back electric vehicles previously was range, which has been solved.
Are you buying when the CEOs of the Magnificent 7 are selling?
<ul>
<li>Stay in the know with our Insider Trades page — <a href="https://www.benzinga.com/sec/insider-trades/">see when leaders like Mark Zuckerberg, Elon Musk, and Jensen Huang are offloading their own shares.</a></li>
</ul>
Why It's Important: While investors and analysts wanted to hear about Musk's relationship with Trump, what his role<a href="https://www.benzinga.com/news/global/24/11/41927289/trump-appoints-elon-musk-and-vivek-ramaswamy-to-lead-doge-targeting-bureaucracy-and-65-trillion-federal-spending-we-will-not-go-gently"> at the D.O.G.E. </a>means for his time commitment at Tesla and how Trump's EV policies could shape the industry, the earnings call left many questions unanswered.
Trump has been a vocal critic of electric vehicles and also previously said he would ban autonomous vehicles from U.S. roads, a move that would severely hurt the future growth plan of Tesla and its robotaxis.
New Transportation Secretary Sean Duffy shared in a memo that the previous push by Joe Biden's administration for electric vehicles was "forced" on people.
Musk's comments about the future being all-electric and autonomous go against the commentary of Trump and his administration, which could make the friendship between the billionaire and president an interesting development to watch as Musk will likely have to push for support of autonomous vehicles.
Rivian Automotive CEO RJ Scaringe recently <a href="https://www.benzinga.com/25/01/43279098/rivian-ceo-brushes-off-7500-electric-vehicle-tax-credit-concerns-evs-are-not-a-political-thing">shared a similar commentary</a> of keeping his eyes on the future and ignoring the short-term "speed bumps" created by items like the end of the federal tax credit.
&#8220;I started the company with the view of making highly compelling products, and none of my decision to start Rivian had anything to do with what the policy was going to look like,&#8221; Scaringe said.
Scaringe said that the potential elimination of the $7,500 tax credit would be &#8220;equally applied to all,&#8221; which could mean a level playing field for all companies in the electric vehicle sector.
&#8220;The future of transportation will be electric.&#8221;
Scaringe said policy revisions like this can&#8217;t slow down the long-term trend of electric vehicle growth and the necessity of having more electric vehicles on the road.
&#8220;This is not a political thing. It&#8217;s not like the left wants to move to electrification. It&#8217;s that the future of transportation will be electric.&#8221;
Watch the Tesla fourth-quarter earnings call with Musk below. 
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/01/43347509/tesla-stock-analysts-highlight-fsd-robotaxis-new-vehicles-for-growth-elon-has-never-sounded-so-bullish">Tesla Analysts Highlight FSD, Robotaxis, New Vehicles For Growth: &#8216;Elon Has Never Sounded So Bullish&#8217;</a></li>
</ul>
Photo: Shutterstock
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="&#x1f534; WATCH LIVE: Tesla Q4 2024 Earnings Call &#x7C; $TSLA" width="500" height="281" src="https://www.youtube.com/embed/G2UrBRGrLb0?feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>

Earnings

Politics

Elon Musk Brushes Aside Concerns On Trump's EV Policies: 'Sustainable Transport Is Inevitable … It Can't Be Stopped'

UBS analyst Karl Keirstead maintains Microsoft (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) with a Buy and lowers the price target from $525 to $510.

UBS Maintains Buy on Microsoft, Lowers Price Target to $510

UBS analyst Jay Sole maintains VF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VFC#NYSE">VFC</a>) with a Neutral and raises the price target from $24 to $28.

UBS Maintains Neutral on VF, Raises Price Target to $28

UBS analyst Lloyd Walmsley maintains Meta Platforms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) with a Buy and raises the price target from $736 to $786.

UBS Maintains Buy on Meta Platforms, Raises Price Target to $786

UBS analyst Joseph Spak maintains Tesla (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) with a Sell and raises the price target from $226 to $259.

UBS Maintains Sell on Tesla, Raises Price Target to $259

UBS analyst Ashwani Verma maintains Neurocrine Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBIX#NASDAQ">NBIX</a>) with a Buy and raises the price target from $162 to $176.

NBIX

UBS Maintains Buy on Neurocrine Biosciences, Raises Price Target to $176

AbbVie (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) has outperformed the market over the past 5 years by 2.84% on an annualized basis producing an average annual return of 15.8%. Currently, AbbVie has a market capitalization of $310.89 billion. 
Buying $100 In ABBV: If an investor had bought $100 of ABBV stock 5 years ago, it would be worth $213.43 today based on a price of $175.93 for ABBV at the time of writing.
<h3>AbbVie's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1738278910_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ABBV

$100 Invested In AbbVie 5 Years Ago Would Be Worth This Much Today

TD Securities analyst Craig Hutchison maintains MAG Silver (TSX:<a class="ticker" href="https://www.benzinga.com/stock/MAG#TSX">MAG</a>) with a Buy and raises the price target from C$26 to C$27.

TSX:MAG

TD Securities Maintains Buy on MAG Silver, Raises Price Target to C$27

TD Securities analyst Daniel Chan maintains CGI (TSX:<a class="ticker" href="https://www.benzinga.com/stock/GIB#TSX">GIB</a>) with a Buy and raises the price target from C$180 to C$190.

TSX:GIB

TSX:GIB/A

TD Securities Maintains Buy on CGI, Raises Price Target to C$190

Citigroup analyst Ronald Josey maintains Meta Platforms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) with a Buy and raises the price target from $753 to $780.

Citigroup Maintains Buy on Meta Platforms, Raises Price Target to $780

Citigroup analyst Jon Tower maintains Brinker International (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EAT#NYSE">EAT</a>) with a Neutral and raises the price target from $166 to $185.

Citigroup Maintains Neutral on Brinker International, Raises Price Target to $185

Citigroup analyst Scott Gruber maintains Seadrill (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SDRL#NYSE">SDRL</a>) with a Buy and lowers the price target from $50 to $46.

SDRL

Citigroup Maintains Buy on Seadrill, Lowers Price Target to $46

American Express (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AXP#NYSE">AXP</a>) has outperformed the market over the past 5 years by 6.37% on an annualized basis producing an average annual return of 19.32%. Currently, American Express has a market capitalization of $223.90 billion. 
Buying $100 In AXP: If an investor had bought $100 of AXP stock 5 years ago, it would be worth $243.47 today based on a price of $318.95 for AXP at the time of writing.
<h3>American Express's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1738278015_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning American Express Stock In The Last 5 Years

Citigroup analyst Scott Gruber maintains Valaris (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VAL#NYSE">VAL</a>) with a Neutral and raises the price target from $47 to $48.

Citigroup Maintains Neutral on Valaris, Raises Price Target to $48

Citigroup analyst Asiya Merchant maintains Western Digital (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WDC#NASDAQ">WDC</a>) with a Buy and lowers the price target from $82 to $80.

Citigroup Maintains Buy on Western Digital, Lowers Price Target to $80

Citigroup analyst Patrick Donnelly maintains Danaher (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>) with a Buy and lowers the price target from $285 to $265.

Citigroup Maintains Buy on Danaher, Lowers Price Target to $265

Citigroup analyst George Choi maintains Las Vegas Sands (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LVS#NYSE">LVS</a>) with a Buy and raises the price target from $64.5 to $67.

Citigroup Maintains Buy on Las Vegas Sands, Raises Price Target to $67

Press Releases

Dr. Ryan Saadi Commends Individuals Who Dedicate Time to Public Service, and Congratulates Mayor Victor Sordillo on His Induction Into the NJ League of Municipalities Hall of Fame

Health Care

Tevogen Bio to Attend the 43rd Annual J.P. Morgan Healthcare Conference

Tevogen Bio to Host Panel "Pioneering the Economics of Health: Balancing Access and Outcomes" During the 43rd Annual J.P. Morgan Healthcare Conference

Legal

Tevogen Bio Strengthens Robust IP Portfolio With Filing of Predictive AI Patent, With the Goal to Establish a Blueprint to Unlock the Full Potential of T Cell Therapies and Accelerate AI Integration to Advance Its Bold Growth Agenda

Tevogen Bio to Host Panel "AI In Biopharma: Next Frontier of Medical Innovation" During the 43rd Annual J.P. Morgan Healthcare Conference

Tevogen Bio to Host Panel Discussions "AI In Biopharma: Next Frontier of Medical Innovation" and "Pioneering the Economics of Health: Balancing Access and Outcomes" During J.P. Morgan Healthcare Conference

Comments

Tevogen Bio Holdings

Tevogen Bio Holdings (TVGN) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga